Australia markets close in 3 hours 20 minutes

  • ALL ORDS

    7,079.20
    +36.50 (+0.52%)
     

  • ASX 200

    6,821.60
    +32.00 (+0.47%)
     

  • AUD/USD

    0.7750
    -0.0027 (-0.35%)
     

  • OIL

    60.01
    -0.63 (-1.04%)
     

  • GOLD

    1,715.80
    -7.20 (-0.42%)
     

  • BTC-AUD

    63,391.96
    +3,002.10 (+4.97%)
     

  • CMC Crypto 200

    983.69
    +55.46 (+5.97%)
     

  • AUD/EUR

    0.6440
    -0.0010 (-0.16%)
     

  • AUD/NZD

    1.0682
    -0.0008 (-0.08%)
     

  • NZX 50

    12,396.41
    +94.60 (+0.77%)
     

  • NASDAQ

    13,282.95
    +373.51 (+2.89%)
     

  • FTSE

    6,588.53
    +105.10 (+1.62%)
     

  • Dow Jones

    31,535.51
    +603.14 (+1.95%)
     

  • DAX

    14,012.82
    +226.53 (+1.64%)
     

  • Hang Seng

    29,708.39
    +255.82 (+0.87%)
     

  • NIKKEI 225

    29,758.79
    +95.29 (+0.32%)
     
✉️ Free sign-up:

Get the news straight to your inbox every day.

Stay in the loop every day with Yahoo Finance's free Fully Briefed newsletter.

2020 Insights on the European Parcels Market - Featuring UPS, FedEx and Royal Mail Group Among Others - ResearchAndMarkets.com

·3-min read

The "European Parcels: Market Insight Report 2020" report has been added to ResearchAndMarkets.com's offering.

This report sets out the market structure, size, growth, key trends and competitive landscape, covering eight main countries in depth: Germany, UK, France, Spain, Italy, Netherlands, Belgium and Poland. These markets represent 76% of European GDP and, according to the market model, 81% of total parcels revenues.

The other countries included in the continent-wide overview and market size estimates are Switzerland, Sweden, Norway, Austria, Denmark, Greece, Finland, Portugal, Ireland, Czech Republic, Romania, Hungary, Slovak Republic, Croatia, Bulgaria, Slovenia, Serbia, Lithuania, Latvia, Luxembourg, Estonia, Bosnia and Herzegovina, Iceland, Albania, FYR Macedonia, Malta and Montenegro. Russia and Turkey are excluded.

The publisher's definition of the parcels market includes domestic, intra-European and international parcels. It also includes business-to-business, business-to-consumer and consumer consigned parcels.

  • Parcel weight definitions vary, between operators and countries, but most describe parcels up to various weights approaching 40 kg.

  • All service levels are included (time definite and deferred).

  • Adjacent services, such as mail, pallet distribution, groupage, freight forwarding, same day delivery fulfilment and contract logistics are excluded.

The report provides historical and forecast market sizes covering the period from 2014-2024.

  • Market sizes are presented in value and volume terms.

  • Market values are presented on a constant currency basis.

  • The market is segmented by country and, within each country and at the overall European level, between B2B, B2C and C2X.

The report includes in-depth profiles of the European operations of the following groups:

  • DP DHL

  • UPS

  • FedEx (including TNT)

  • Royal Mail Group

  • Le Groupe La Poste/DPD

  • Hermes

  • Poste Italiane

  • Amazon Logistics

The report draws on:

  • The publisher's work on the parcels markets in several key countries and regions

  • Their consulting work in the industry which has included advising on market and strategic issues and the attractiveness of parcel company acquisitions

Key Topics Covered:

About this report

  • Background to the report

  • What does the report cover?

  • What are the sources and methodology?

  • Who is it useful for?

  • Who wrote the report?

Summary

Market size and growth

Market trends

Competitive landscape

  • Outlook

About the Publisher: Parcels & Logistics Research Highlights

About the Publisher: recent parcels, transport and logistics consulting experience

About the Publisher: example parcels/delivery research and consulting clients

Contents

  • List of Charts and Tables

  • European Parcels Market Background

Market Definition

  • Characteristics of the market

  • Business vs. consumer delivery

  • Other segmentations of the market

  • Premium/economy

  • International/domestic

  • The Impact of COVID-19 Lockdown

  • The Impact of COVID-19 on GDP

  • Impact on retailer performance

  • The Impact of COVID-19 on parcel carrier revenue and volume

  • Carrier comments on 2020 trading

Profiles of Leading Groups

  • DPDHL

  • UPS (Europe)

  • Recent developments

  • FedEx

  • Recent developments

  • Royal Mail Group

  • Le Groupe La Poste/DPD

  • Parcels (within Services-Mail-Parcels)

  • GeoPost

  • Recent developments

  • Hermes

  • Recent developments

  • Poste Italiane

  • Amazon Logistics

  • Network of facilities

  • Development of core delivery operations

  • Amazon's delivery model

  • Additional services

  • Shipping with Amazon

  • Implications for other carriers

  • Other European networks

  • Eurodis

  • Net Express Europe

  • GO! (General Overnight)

For more information about this report visit https://www.researchandmarkets.com/r/gzeyqz

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005256/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Latest stories

  • Oil Sinks Toward $60 Before OPEC+ Meets to Decide on Supplies

    (Bloomberg) -- Oil sank below $60 a barrel in Asian trading amid growing concern over this week’s OPEC+ output-setting meeting.Futures in New York fell for a third day, putting them on course for the worst run of losses since December. The alliance gathers on Thursday to decide how many barrels to return to a market that had its best ever start to a year before the current skid. Ahead of the gathering, Saudi Arabia has urged members to take a cautious approach even as signs of tightening emerge.Crude roared higher in the opening two months of 2021, aided by the deep OPEC+ supply cuts, which include unilateral reductions by the Saudis. The roll-out of vaccines and an investor charge into commodities has also underpinned the gains, which pushed prices in New York to the highest close since 2019.Investors are “a little bit unsure whether OPEC will continue with the support they provided over the last few months with the supply cuts,” said Daniel Hynes, a senior commodity strategist at Australia & New Zealand Banking Group Ltd. If there’s a higher-than-expected increase, that could make things difficult in the short term given demand is still showing signs of fragility, he said.The Organization of Petroleum Exporting Countries and its allies must decide how much output gets restored -- and at what pace -- with current reductions amounting to just over 7 million barrels a day, or 7% of global supply. Citigroup Inc. thinks the coalition will boost output by about 500,000 barrels a day next month, with Saudi Arabia unlikely to continue its voluntary curbs.While the pandemic has lessened as a concern for investors as vaccination campaigns intensify, the World Health Organization warned Monday a potent threat remains. Global cases rose for the first time in almost two months in the past week, WHO officials said at a media briefing Monday.Brent’s prompt timespread was 67 cents a barrel in backwardation on Monday. While that’s a bullish structure -- with near-dated prices above later-dated ones -- it’s the lowest reading since mid-February.As OPEC+ weighs how many barrels to release, group leaders Saudi Arabia and Russia need to judge the likely response by U.S. shale producers. While most big publicly traded explorers in the U.S. are planning to keep output flat, smaller, private companies are seeking to grow supply after this year’s rally.The runway to the Thursday’s full OPEC+ meeting starts later Tuesday with the group’s Joint Technical Committee gathering. The JTC’s role is to review the market conditions and members’ conformity levels with supply agreements.Traders and producers will be mindful last year’s March OPEC+ meeting ended in failure. Saudi Arabia and Russia failed to strike an accord, sparking a price war as output surged. That devastated prices just as the pandemic intensified.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Verra Mobility (VRRM) Q4 2020 Earnings Call Transcript

    With me on the call this afternoon is David Roberts, Verra Mobility's Chief Executive Officer; and Tricia Chiodo, Chief Financial Officer. During the call, we will make statements related to our business that may be considered forward-looking, including statements concerning our plans to execute on our growth strategy, our ability to maintain existing and acquire new customers, and other statements regarding our plans and prospects.

  • Orasure Technologies Inc (OSUR) Q4 2020 Earnings Call Transcript

    OSUR earnings call for the period ending December 31, 2020.

  • Regenxbio Inc. (RGNX) Q4 2020 Earnings Call Transcript

    With us are Ken Mills, REGENXBIO's President and Chief Executive Officer, Dr. Steve Pakola, our Chief Medical Officer, Dr. Olivier Danos our Chief Scientific Officer, and Vit Vasista, our Chief Financial Officer. Earlier this afternoon, REGENXBIO released financial and operating results for the fourth quarter and full year ended December 31, 2020.

  • Anzu Special Acquisition Corp I Announces Pricing of Upsized $420,000,000 Initial Public Offering

    Anzu Special Acquisition Corp I (NASDAQ: ANZUU) (the "Company") today announced the pricing of its initial public offering of 42,000,000 units at a price of $10.00 per unit. Each unit consists of one share of the Company’s Class A common stock and one-third (1/3) of one redeemable warrant of the Company. Each whole warrant entitles the holder to purchase one share of the Company’s Class A common stock at a price of $11.50 per share, and only whole warrants are exercisable. The units will be listed on the Nasdaq Capital Market (the "Nasdaq") and are expected to trade under the ticker symbol "ANZUU" beginning Tuesday, March 2, 2021. Once the securities comprising the units begin separate trading, the shares and warrants are expected to be traded on the Nasdaq under the symbols "ANZU" and "ANZUW," respectively. The offering is expected to close on March 4, 2021, subject to customary closing conditions.

  • Emerging Therapeutics to boom AL Amyloidosis Treatment Synopsis

    Advances in the AL Amyloidosis clinical trials promote treatment as 15+ companies are working towards the development of novel approaches.Los Angeles, March 01, 2021 (GLOBE NEWSWIRE) -- Emerging Therapeutics to boom AL Amyloidosis Treatment Synopsis Advances in the AL Amyloidosis clinical trials promote treatment as 15+ companies are working towards the development of novel approaches. DelveInsight’s “Amyloid light-chain Amyloidosis (AL) Pipeline Insight'' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Amyloid light-chain Amyloidosis pipeline landscapes. It comprises AL Amyloidosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Amyloid light-chain Amyloidosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive AL Amyloidosis pipeline products. Some of the important features of the AL Amyloidosis Pipeline Report The companies such as Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and several others are working on novel approaches for AL Amyloidosis treatment. In January 2019, Alexion Pharmaceuticals and Caelum Biosciences declared a collaboration to develop CAEL-101 for light chain (AL) amyloidosis. CAEL-101 has secured Orphan Drug Designation from both the US Food and Drug Administration (FDA) and European Medicine Agency as a therapy for AL amyloidosis patients.In May 2020, Sorrento Therapeutics announced it had received clearance from the FDA for its investigational new drug (IND) application for STI-6129. Request for sample pages @ Amyloid light-chain Amyloidosis Pipeline Insight Report Amyloid Light-chain Amyloidosis (AL) is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. It is caused by a bone marrow disorder. AL amyloidosis diagnosis requires demonstration of amyloid in tissue and demonstration of a plasma cell dyscrasia. The current therapeutic approach to systemic amyloidosis is based on the observations that organ dysfunction enhances and survival increases if the synthesis of the amyloidogenic protein precursor is stopped. The AL amyloidosis therapy aims to rapidly reduce the supply of amyloidogenic monoclonal light chains by repressing the underlying plasma cell dyscrasia. AL Amyloidosis Emerging Drugs CAEL-101 by Caelum Biosciences CAEL-101 is a fibril-reactive monoclonal antibody (mAb) that is currently in phase III clinical development for the treatment of amyloid light-chain (AL) amyloidosis patients. Bendamustine by Astellas Pharma GmbH Astellas Pharma GmbH is developing bendamustine for the AL amyloidosis treatment. It is currently in the phase II stage of development. STI-6129 by Sorrento Therapeutics STI-6129, a CD38-targeting antibody-drug conjugate (ADC) that is being developed by Sorrento Therapeutics to treat Amyloid light-chain Amyloidosis. It is currently in the phase I stage of development. For further product profiles, request @ Amyloid light-chain Amyloidosis Pipeline Insight Report Scope of AL Amyloidosis Pipeline Drug Insight Coverage: Global Major Players: 15+ Key PlayersProminent Players: Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and many others. Key Drugs Profiles: 15+ Products Phases: Amyloid Light-chain Amyloidosis Late-stage (Phase III) AL Amyloidosis Therapies (Phase II)Amyloid Light-chain Amyloidosis Therapies (Phase I) AL Amyloidosis Pre-clinical stage and Discovery candidates Discontinued and Inactive candidates Molecule Types: Gene therapiesSmall moleculeVaccinesPolymersPeptidesMonoclonal antibodies Mechanism of Action: Protease inhibitors Immunomodulatory Multiple kinase inhibitor Route of Administration: InfusionIntradermalIntramuscularIntranasalIntravaginalOralParenteralSubcutaneousTopical Product Types: Monotherapy Combination  Key Questions regarding Current AL Amyloidosis Treatment Landscape and Emerging Therapies Answered in the Pipeline Report What are the current options for Amyloid light-chain Amyloidosis treatment?How many companies are developing therapies for the treatment of AL Amyloidosis? How many are Amyloid light-chain Amyloidosis emerging therapies in the early-stage, mid-stage, and late stages of development for the treatment of AL Amyloidosis?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Amyloid light-chain Amyloidosis market? Which are the dormant and discontinued products and the reasons for the same?What is the unmet need for current therapies for the treatment of AL Amyloidosis? What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Amyloid light-chain Amyloidosis therapies? What are the critical designations that have been granted for the emerging therapies for AL Amyloidosis? How many patents are granted and pending for the emerging therapies to treat Amyloid light-chain Amyloidosis? Table of Contents 1Amyloid light-chain Amyloidosis Introduction2AL Amyloidosis Executive Summary3Amyloid light-chain Amyloidosis Overview4AL Amyloidosis Analytical Perspective In-depth Commercial Assessment 5Amyloid light-chain Amyloidosis Pipeline Therapeutics5.1AL Amyloidosis Late Stage Products (Phase III)5.1.1CAEL-101: Caelum Biosciences5.2Amyloid light-chain Amyloidosis Early Stage Products (Phase I/II)5.2.1Melphalan flufenamide: Oncopeptides5.3AL Amyloidosis Early Stage Products (Phase I)5.3.1STI-6129: Sorrento Therapeutics5.4AL Amyloidosis Pre-clinical and Discovery Stage Products6Amyloid light-chain Amyloidosis Therapeutic Assessment7AL Amyloidosis Inactive Products8Company-University Collaborations (Licensing/Partnering) Amyloid light-chain Amyloidosis Analysis9AL Amyloidosis Key Companies10Amyloid light-chain Amyloidosis Key Products11 AL Amyloidosis Unmet Needs12Amyloid light-chain Amyloidosis Market Drivers and Barriers13AL Amyloidosis Future Perspectives and Conclusion14Amyloid light-chain Amyloidosis Analyst Views15Appendix16About DelveInsight Get customized pipeline report @ AL Amyloidosis Drug Treatment Related Reports AL Amyloidosis Market Analysis DelveInsight’s AL Amyloidosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. AL Amyloidosis Epidemiology Forecast Analysis DelveInsight's AL Amyloidosis Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of AL Amyloidosis. Hereditary ATTR (hATTR) amyloidosis Market Analysis DelveInsight's Hereditary ATTR (hATTR) amyloidosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. Hereditary Transthyretin Amyloidosis (hATTR)- Competitive Landscape, Market Insights, Epidemiology, and Market Forecast-2030 DelveInsight's "Hereditary Transthyretin Amyloidosis (hATTR) amyloidosis Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. Transthyretin Amyloidosis (ATTR) Market Analysis DelveInsight's Transthyretin Amyloidosis (ATTR) - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Familial Amyloid Polyneuropathy Market Analysis DelveInsight' s Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology. Palmar Hyperhidrosis Market Analysis DelveInsight's Palmar Hyperhidrosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. About DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. CONTACT: Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com

  • VBCE and EMQ Team Up to Expand Global Payment Capabilities

    VBCE and EMQ Team Up to Expand Global Payment Capabilities

  • AI Driven Application Innovator, EverestIMS Technologies signs distribution agreement with Australia-based AppDistri

    EverestIMS Technologies is happy to announce a partnership with Australia based AppDistri.

  • 'Surprising' $16.99 Aldi budget buy rivals $80 version

    A dress at Aldi has caused a serious stir after shoppers claimed it is 'identical' to a piece almost five times the price.

  • Have You Lost Money Investing In Athenex, Inc. Securities? – Kehoe Law Firm, P.C. Class Action Investigation On Behalf Of ATNX Investors Who Have Suffered Losses Greater Than $50,000

    PHILADELPHIA, March 01, 2021 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) to determine whether the Company engaged in securities fraud or other unlawful business practices. Shares of Athenex dropped significantly after the Company reported Q4 results and received a complete response letter from the FDA expressing concerns about the Company’s new drug application for a drug which treats metastatic breast cancer. INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, ATNX SECURITIES AND SUFFERED LOSSES GREATER THAN $50,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT KEVIN CAULEY, DIRECTOR, BUSINESS DEVELOPMENT, (215) 792-6676, EXT. 802, KCAULEY@KEHOELAWFIRM.COM, SECURITIES@KEHOELAWFIRM.COM, INFO@KEHOELAWFIRM.COM, TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION OR POTENTIAL LEGAL CLAIMS. Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors. This press release may constitute attorney advertising.

  • Andy Murray gets first ATP win in six months

    The former World No.1 wins in Rotterdam. Source: Tennis TV

  • US sanctions expected over Navalny

    The United States is reportedly expected to impose sanctions as early as this week on Russians connected to the poisoning of Kremlin critic Alexei Navalny.Sources are declining to identify the targets or legal authorities Washington would use to penalise them as it seeks to impose consequences for the poisoning of Navalny.

  • Tedesco sets sights on premiership greats

    James Tedesco has set his sights on being among the Sydney Roosters' greatest premiership winners, determined to add to his illustrious list of honours at the NRL club.Tedesco inked a new deal with the Roosters in December, keeping him there until 2024 and potentially paving the way for him to one day be discussed as a club great.

  • Pandemic-consumed US relapses in drug addiction

    Beverly Veres' two sons are addicted to heroin but can't get the help they need, with US health services consumed by the coronavirus pandemic at a time when overdoses are surging.

  • UPDATE 1-Lawsuit accuses Amazon of 'systemic' racism in corporate offices

    A manager at Amazon.com Inc sued the online retailer for discrimination on Monday, saying it hires Black people for lower positions and promotes them more slowly than white workers, and that she was subjected to harassment. The lawsuit from Charlotte Newman, a business development head at Amazon Web Services who is Black, said the company suffers from a "systemic pattern of insurmountable discrimination," despite its pledge to fight racism and statements of solidarity from Chief Executive Officer Jeff Bezos. Seattle-based Amazon said it was investigating the claims.

  • No hello, eyes down was sus: accused cop

    A cop walks into a bar, greets a seated female patron, is shoved so hard he loses his balance and is crudely told to get lost.But Senior Constable Mark Follington now admits the story he wrote after violently arresting Anya Bradford in 2019 was very different to what occurred.

  • FOREX-Dollar holds advantage over low-yielders, A$ looks to RBA

    The dollar stood firm against its low-yielding peers on Tuesday on bets of a faster economic recovery and greater tolerance of higher U.S. bond yields, while the Australian dollar looked to guidance from the country's central bank. The common currency was under pressure as top officials from the European Central Bank sounded alarm over rises in bond yields. President Christine Lagarde said on Monday the ECB will prevent a premature increase in borrowing costs for firms and households.

  • CPI Card Group Inc. Announces Pricing of Private Offering of $310 Million of Senior Secured Notes

    CPI Card Group Inc. Announces Pricing of Private Offering of $310 Million of Senior Secured Notes

  • Disney CEO says households without kids have boosted streaming success

    Surprisingly strong interest from adults who do not have kids at home has helped increase subscriptions to Walt Disney Co's Disney+ streaming service beyond initial projections, Chief Executive Bob Chapek said on Monday. Disney+ debuted in November 2019 and growth has exceeded Wall Street expectations and Disney's forecast. While Disney is known for family entertainment, Disney+ also features movies and TV shows from Marvel, "Star Wars" studio Lucasfilm and others.

  • Bitcoin Rises as Citi, Goldman Find Crypto Allure Hard to Resist

    (Bloomberg) -- Bitcoin touched the $50,000 level in Asia trading, riding a broad resurgence in risk assets, with Citigroup Inc. and Goldman Sachs Group Inc. warming up to the largest cryptocurrency.The digital asset climbed as much as 2.8% Tuesday, and was holding at $49,080 as of 9:05 a.m. in Hong Kong. Prices last week suffered the worst decline since March and dipped as low as $43,000 on Sunday. Bitcoin climbed to a record $58,350 on Feb. 21.Bitcoin and other cryptocurrencies are drawing increasing attention from mainstream financial institutions and Wall Street players, alongside a growing focus from goverment regulators as well, as the nascent industry’s outlook continues to be subject to furious debate. Proponents point to growing institutional adoption while detractors warn prices are in a speculative bubble.Cboe Global Markets Inc. disclosed it is seeking approval to list and trade shares of what could be the first Bitcoin exchange-traded fund in the U.S., according to a Monday regulatory filing. Meanwhile New York Attorney General Letitia James issued an investor alert on the industry, warning consumers about its susceptibility to “speculative bubbles” and abuse by criminals.In a report by Citigroup’s Global Perspectives & Solutions, strategists laid out a case for Bitcoin to play a bigger role in the global financial system, saying the cryptocurrency could become “the currency of choice for international trade” in the years ahead. Bitcoin has advantages over the current global payment system, such as its decentralized design, lack of foreign exchange exposure and traceability, the strategists said.Goldman is restarting a trading desk for cryptocurrencies, a person familiar with the effort said. The Wall Street bank will begin offering Bitcoin futures among other products by mid-March after halting a similar effort started in 2018, according to the person, who asked to to be named because the plans haven’t been announced.“The more banks that come out with constructive comments on Bitcoin, the more likely the speculative bubble will continue to grow,” said Ed Moya, senior market analyst for OANDA.Citigroup’s full-throated backing of Bitcoin shows that crypto is continuing to win over the world’s biggest financial institutions. Dan Loeb, head of Third Point LLC, said in a Twitter post that he’s been “doing a deep dive into crypto lately,” adding that “it is a real test of being intellectually open to new and controversial ideas.”While banks continue to dip their toes deeper into the world of digital assets, a small group of corporations are busy snapping up coins to add to their balance sheets. MicroStrategy Inc., announced Monday that it purchased an additional 328 Bitcoins, increasing its pile to about 90,859. The company’s holdings are now worth over $4 billion.Bitcoin plunged 21% last week as investors dumped speculative assets amid a run-up in bond yields. The volatility has raised questions about whether it can act as a store of value and hedge against inflation. Detractors have maintained the digital asset’s surge is a speculative bubble and it’s destined for a repeat of the 2017 boom and bust.“Bitcoin’s wild ride is far from over, but it seems another attempt at $50,000 could be in the cards if the bond rout is truly over,” Moya said. “Bitcoin can survive a steady rise in Treasury, but not a skyrocketing move like we saw last week.”Crypto MiningElsewhere, China’s Inner Mongolia banned cryptocurrency mining and declared it will shut all such projects by April, spurring concern the communist nation will take more steps to eradicate the power-hungry practice.The autonomous region, a favorite among the industry because of its cheap power, also banned new digital coin projects, according to a draft plan posted on the Inner Mongolia Development and Reform Commission’s website Feb. 25. The aim is to constrain growth in energy consumption to about 1.9% in 2021.The sheer amount of energy needed to mine Bitcoin and the prospect that governments will create more obstacles for the largest cryptocurrency point to the token losing “most of its value over time,” BCA Research Chief Global Strategist Peter Berezin wrote in the report released Friday.(Updates with latest Bitcoin price, additional details.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.